BBIO vs SNN: Which Stock Is the Better Buy?
BridgeBio Pharma, Inc. and Smith & Nephew plc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BBIO vs SNN, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| BridgeBio Pharma, Inc. (BBIO) | Smith & Nephew plc (SNN) | |
|---|---|---|
| Market cap | $13.3B | $12.9B |
| Revenue (latest FY) | $502.08M | $6.16B |
| Net income (latest FY) | $-724.93M | $625.00M |
| Revenue growth (5y CAGR) | 127.4% | 5.7% |
| Net margin | -144.4% | 10.1% |
| Return on equity | 34.7% | 11.8% |
| P/E ratio | — | 21.3 |
| Dividend yield | — | 2.5% |
| Profitable years (of last 10) | 0 | 4 |
| Positive free cash flow | No | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full BBIO vs SNN breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BBIO's full financials → Open SNN's full financials →More comparisons
Frequently asked questions
Which is bigger, BBIO or SNN?
BridgeBio Pharma, Inc. is larger by market capitalization — $13.3B versus $12.9B.
Which grows faster, BBIO or SNN?
Over the last five fiscal years, BridgeBio Pharma, Inc. grew revenue faster — 127.4%/yr versus 5.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.